Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs to sharpen focus, meet competition

Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it would cut 9,000 jobs, 5,000 of them in Denmark, in order to strengthen the company’s focus on growth opportunities in obesity and diabetes medications

The Independent UK

Wegovy maker Novo Nordisk to cut 9,000 jobs amid increased competition

Danish manufacturer of weight-loss and diabetes drugs under pressure from US rival Eli Lilly

The Guardian - UK

Trump reportedly asks EU to levy 100% tariffs on India and China; Ozempic maker Novo to cut 9,000 jobs – as it happened

US president wants to up pressure on Russia to end war in Ukraine

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Ozempic Is The New Botox And Big Pharma Is Printing Billions

Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) achieve a combined market cap topping $900 billion. Celebrities flaunt it, Silicon Valley elites swear by it, and analysts predict the GLP-1 market could surpass $150 billion…

Benzinga

WHO has added GLP-1 drugs to the essential medicines list. Here’s what that means

GLP-1 drugs were initially developed for diabetes, but have become wildly popular weight-loss drugs too

The Independent UK

Scientists say there is no link between ‘microdosing’ weight-loss drugs and living longer

It is ‘too early’ to know whether small doses of weight-loss drugs can help you live longer, experts say

The Independent UK

After Copycat Boom, China's Drugmakers Target Global Generics

China-based drugmakers that once fueled a surge of copycat weight-loss treatments in the U.S. are now pivoting to generics of Novo Nordisk‘s (NYSE:NVO) Wegovy and Eli Lilly's (NYSE:LLY) Zepbound as regulators tighten rules on compounded medicines.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death

Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.

Benzinga

The Ozempic effect: From shopping baskets to dips in Danish GDP

As GLP-1 use spreads, grocers and restaurants see lighter baskets, airlines predict fuel savings and health systems eye lower costs—while Denmark sees a clipped GDP.

Euronews

Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook

Weaker prospects for pharmaceutical giant Novo Nordisk A/S (NYSE:NVS) have prompted Denmark's economic ministry to cut its 2025 GDP forecast, now expecting just 1.4% growth, down 1.5 percentage points from May's projection.

Benzinga

Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda

As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major players to seek FDA approvals for generic versions of popular medications, reshaping the competitive landscape and providing more choices for consumers.

Benzinga

Pregnant women face tough choices about medication use due to lack of safety data − here’s why medical research cuts will make it worse

A panel convened in July 2025 by the Food and Drug Administration sparked controversy by casting doubt about the safety of commonly used antidepressants during pregnancy. But it also raised the broader issue of how little is known about the safety of many medications used in pregnancy, considering the implications…

The Conversation

FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles

The U.S. Food and Drug Administration (FDA) has identified repeated quality control failures, including foreign particle contamination, inadequate investigations, and insufficient corrective actions at the Novo Nordisk A/S (NYSE:NVO) operated facility in Bloomington, Indiana.

Benzinga

Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers

Hims Hers Health Inc (NYSE:HIMS) investors can’t catch a break. Less than two months since Novo Nordisk AS (NYSE:NVO) terminated its Wegovy partnership with the telehealth company abruptly, the pharma giant is again in the news, this time partnering with GoodRx Holdings Inc (NASDAQ:GDRX) to provide discounted access to Ozempic…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Kiplinger

I'm a Financial Pro: Why You Shouldn't Put All Your Eggs in the Company Stock Basket

Limit exposure to your employer's stock, sell it periodically and maintain portfolio diversification to protect your wealth from unexpected events.

The Independent UK

Voices: British Mounjaro users face a shortage and tripling prices: Think alternatives, not cold turkey

COMMENT: With Mounjaro supplies to the UK on pause, and private prescription costs set to exceed £300 from September, it’s worrying news for the half a million Brits already using weight-loss jabs. Here, doctor and epidemiologist Tim Spector assesses alternative options

Benzinga

Options Corner: Embattled Drug Maker Novo Nordisk May Offer Speculators A Quick Profit-Scalping Opportunity

From the doldrums of the COVID-19 crisis to the early summer of 2024, few major pharmaceutical companies enjoyed as much market success as Novo Nordisk (NYSE:NVO). Much of the success was tied into the company's weight-loss drugs Wegovy and Ozempic. However, competition in the space has intensified, particularly from Eli…

Bored Panda

People Are Experiencing Such Bad Ozempic Side Effects That It Might Result In $2B In Lawsuits

Ozempic reportedly faces around $2 billion in lawsuits that are about its side effects.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Novo Nordisk Freezes Hiring As Wegovy Faces Copycats

Novo Nordisk A/S (NYSE:NVO) has reportedly imposed a global hiring freeze for nonessential roles, as the drugmaker faces rising competition from copycat versions of Wegovy and intensifying rivalry with Eli Lilly and Co (NYSE:LLY).

Benzinga

What's Going On With Hims & Hers Shares Today?

Hims Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after GoodRx Inc. (NASDAQ:GDRX) announced a collaboration with Novo Nordisk to provide discounted access to two of the most in-demand GLP-1 drugs, Ozempic and Wegovy.

International Business Times UK

Market Bloodbath: Viking Therapeutics Stock Tanks After Obesity Pill Side Effects Trigger Mass Dropouts

Viking Therapeutics shares plunged 40% after trial data for its obesity pill, VK2735, revealed high dropout rates due to side effects, raising doubts about its competitiveness against rivals Eli Lilly and Novo Nordisk.

Benzinga

New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data

Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are expected to launch new obesity-treatment pills in the U.S. next year at prices comparable to their existing injectable drugs, signaling a break from the industry trend of charging more for new therapies.

Benzinga

Ozempic Gains First Approval In Canada For Kidney Disease And Cardiovascular Death Risk

Health Canada on Tuesday approved Novo Nordisk's (NYSE:NVO) Ozempic (semaglutide) to reduce the risk of kidney disease and cardiovascular deaths in adults with type 2 diabetes.

Benzinga

UnitedHealth Vs. Novo Nordisk: Which Healthcare Giant Fits Your Portfolio?

Two healthcare giants, UnitedHealth Group Inc (NYSE:UNH) and Novo Nordisk A/S (NYSE:NVO), are duking it out in very different ways for investors' attention. Both stocks have faced heavy losses this year—UNH down 38.85% YTD, NVO down 38.59%. Yet, their underlying strategies couldn't be more distinct.

Benzinga

GoodRx (GDRX) Stock Is Sliding Tuesday: What's Going On?

GoodRx Holdings Inc (NASDAQ:GDRX) shares are pulling back Tuesday morning, as investors potentially take profits following Monday’s surge. The stock had jumped over 30% Monday after the company announced a new partnership with Novo Nordisk to expand access to popular GLP-1 medications.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.